Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-DOTA-(2P-PEG4)2 is a gallium-68 labeled radiopharmaceutical designed for the positron emission tomography (PET) imaging of prostate cancer. It is a multivalent molecular probe consisting of a PSMA-targeting dimer conjugated to polyethylene glycol (PEG4) chains and a DOTA chelator. The design leverages the multivalent effect to enhance binding affinity to the prostate-specific membrane antigen (PSMA) and utilizes PEGylation to optimize pharmacokinetics, specifically aiming for higher tumor accumulation and rapid renal clearance. In preclinical studies, it demonstrated superior tumor-to-organ ratios compared to monomeric counterparts, making it a promising candidate for the diagnostic localization of PSMA-positive lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [68Ga]Ga-DOTA-(2P-PEG4)2.